BioSpace News Archive

Medovate has announced that it has entered into an agreement with Mercury Medical for exclusive distribution of the FDA-cleared device SAFIRA.

Hoth Therapeutics, Inc. today announced it has signed an agreement with NUVISAN, a European CRO/CDMO with topical manufacturing capabilities in Sophia-Antipolis, France , to manufacture clinical batches of HT-001.

AKSO Biopharmaceutical, Inc. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. announced that the companies have entered into an exclusive collaboration to develop and commercialize AB002, a bi-functional fusion protein inhibiting immune checkpoint and activating natural killer cells for the treatment of solid tumors, in the Asia Pacific Ex-Japan region.

Today, the U.S. Food and Drug Administration took new steps aimed at fostering the development of non-addictive alternatives to opioids to manage acute pain and decreasing exposure to opioids and preventing new addiction.

The arrival of immune checkpoint inhibitors has been reshaping the captivating landscape of cancer immunotherapy.

The aberrant Trop-2 overexpression is associated in several solid tumors including colorectal, lung cancer, and breast cancers.

The mitogen activated protein kinase (MAPK) signaling pathway or Ras/Raf/MEK/ERK pathway is one of the critical pathways involved in signal transduction, which results in the control of cell proliferation, survival, and differentiation

Collaboration enables Merck KGaA, Darmstadt, Germany access to CelerisTx AI platform across two drug discovery projects.

REGENXBIO Inc. announced additional positive interim data from Cohorts 1-3 of the ongoing Phase I/II trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II, also known as Hunter Syndrome, are being presented at the 18th Annual WORLDSymposium™.

The Board of Directors of Sartorius Stedim Biotech S.A. resolved at today’s meeting to submit a proposal to the combined Annual General Shareholders’ Meeting (AGM) on March 29, 2022 , to pay a dividend of 1.26 euros per share for fiscal 2021, up from 0.68 euros per share a year earlier.